Tumor-specific CD4+ T cell responses have traditionally been studied in the ‘post-hoc’ setting following their generation by targeted vaccination, immune checkpoint blockade, or at late stages of tumor outgrowth. The gene discussed is CD4; the disease is neoplasm.